Indaptus initiates unrestricted enrollment on patients on Decoy20 weekly dosing
PremiumThe FlyIndaptus initiates unrestricted enrollment on patients on Decoy20 weekly dosing
29d ago
Indaptus Therapeutics CSO to speak on webinar about cancer immunotherapy
Premium
The Fly
Indaptus Therapeutics CSO to speak on webinar about cancer immunotherapy
1M ago
Indaptus Therapeutics files to sell 1.64M shares of common stock for holders
Premium
The Fly
Indaptus Therapeutics files to sell 1.64M shares of common stock for holders
2M ago
Indaptus Therapeutics Elects Directors and Approves Key Proposals
PremiumCompany AnnouncementsIndaptus Therapeutics Elects Directors and Approves Key Proposals
5M ago
Indaptus Therapeutics announces updated data from Phase 1 Decoy20 trial
Premium
The Fly
Indaptus Therapeutics announces updated data from Phase 1 Decoy20 trial
5M ago
Indaptus Therapeutics to present new cohort data on Phase 1 trial of Decoy20
Premium
The Fly
Indaptus Therapeutics to present new cohort data on Phase 1 trial of Decoy20
6M ago
Indaptus Therapeutics expects cash to support activities through 3Q24
PremiumThe FlyIndaptus Therapeutics expects cash to support activities through 3Q24
8M ago
Indaptus Therapeutics reports 2023 EPS ($1.83) vs. ($1.73) last year
Premium
The Fly
Indaptus Therapeutics reports 2023 EPS ($1.83) vs. ($1.73) last year
8M ago
Indaptus announces results from second cohort in Phase 1 INDP-D101 trial
Premium
The Fly
Indaptus announces results from second cohort in Phase 1 INDP-D101 trial
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100